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An Adenovirus-Vectored Nasal Vaccine Confers Rapid and Sustained
Protection against Anthrax in a Single-Dose Regimen
Jianfeng Zhang,a Edward Jex,a* Tsungwei Feng,a Gloria S. Sivko,b Leslie W. Baillie,c* Stanley Goldman,c Kent R. Van Kampen,a
De-chu C. Tanga*
Vaxin, Inc., Gaithersburg, Maryland, USAa; Battelle Biomedical Research Center, West Jefferson, Ohio, USAb; Biological Defense Research Directorate, Naval Medical
Research Center, Rockville, Maryland, USAc
Bacillus anthracis is the causative agent of anthrax, and its spores have been developed into lethal bioweapons. To mitigate an
onslaught from airborne anthrax spores that are maliciously disseminated, it is of paramount importance to develop a rapid-
response anthrax vaccine that can be mass administered by nonmedical personnel during a crisis. We report here that intranasal
instillation of a nonreplicating adenovirus vector encoding B. anthracis protective antigen could confer rapid and sustained pro-
tection against inhalation anthrax in mice in a single-dose regimen in the presence of preexisting adenovirus immunity. The po-
tency of the vaccine was greatly enhanced when codons of the antigen gene were optimized to match the tRNA pool found in hu-
man cells. In addition, an adenovirus vector encoding lethal factor can confer partial protection against inhalation anthrax and
might be coadministered with a protective antigen-based vaccine.
Anthrax is a naturally occurring bacterial disease caused byBacillus anthracis infection, manifested in cutaneous, gastro-
intestinal, or inhalational form (1). Malicious dissemination of
anthrax spores as an airborne bioweapon is a major biodefense
concern since inhalation of anthrax spores is highly lethal (2). The
harmful impact of anthrax on health is attributed to the produc-
tion of a poly-gamma-D-glutamic acid (PGA) capsule, which con-
fers resistance to phagocytosis postinfection (3), and the produc-
tion of a tripartite exotoxin consisting of protective antigen (PA),
lethal factor (LF), and edema factor (EF) (4). Although antibiotic
therapy is effective against anthrax, latent spores may germinate
many weeks postexposure, requiring prolonged administration of
the antibiotic for full therapeutic effect (5, 6). Vaccination is the
most effective medical intervention against anthrax, either as a
preventative or in conjunction with antibiotic treatment for con-
ferring postexposure prophylaxis (1).
The currently licensed human anthrax vaccine in the United
States is anthrax vaccine adsorbed (AVA; BioThrax), which is pro-
duced by adsorbing cell-free filtrates of microaerophilic cultures
of the B. anthracis V770-NP1-R strain onto aluminum hydroxide
(1). The principal antigenic component of AVA is PA with unde-
fined amounts of LF and EF (7). AVA requires five intramuscular
injections over 18 months plus annual boosters to maintain the
level of protection (8). The administration of AVA is associated
with 1% local, as well as systemic, adverse reactions (8). Al-
though vaccination by injection of AVA confers complete protec-
tion against inhalation anthrax in animal models (9), it is unclear
howwell AVA can protect humans against inhalation anthrax (2).
A variety of next-generation anthrax vaccines designed to address
these issues are currently in development. Ideally, a new anthrax
vaccine should be suitable to rapid mass manufacturing, mass
administration by nonmedical personnel with minimal side ef-
fects, and preferably effective in a single-dose regimen.
Nasal administration of nonreplicating human adenovirus se-
rotype 5 (Ad5)-vectored vaccines mimic a route of natural infec-
tion and stimulate both humoral and cellular immunity systemi-
cally and on mucosal surfaces (10–12). These features make them
ideal for the purpose of intranasal (i.n.) vaccination against patho-
gens.
We have shown previously that mice are protected against tet-
anus by i.n. immunizations with an Ad5 vector encoding tetanus
toxin C fragment (13). We have shown that in the presence of
strong preexisting anti-Ad5 immunity humans can be safely and
effectively immunized with an Ad5-vectored nasal influenza vac-
cine (14). We provide in the present study experimental data that
demonstrate that A/J mice with preexisting immunity to Ad5 can
be immunized and protected by a single i.n. administration with
an Ad5-vectored anthrax vaccine (AdVAV) encoding a codon-
optimized PA gene. In addition, i.n. administration of an Ad5
vector expressing LF induces limited protection against spore in-
fection andmight be used in conjunctionwith a PA-based vaccine.
MATERIALS AND METHODS
Cell culture, medium, and reagents. PER.C6 cells were provided by Cru-
Cell (Netherlands) and cultured in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 10 mM
MgCl2. Contaminant-free human embryonic kidney 293 (HEK293) cells
(Medicine BioServices, Inc., La Jolla, CA) were maintained in RPMI 1640
supplemented with 10% FBS. RAW 264.7 mouse macrophage cells were
purchased from the American Type Culture Collection (ATCC; Manas-
sas, VA) and cultured in DMEM supplemented with 10% FBS. The cells
were incubated at 37°C in 10%CO2. Cell culturemedia and reagents were
purchased fromMediatech, Inc. (Herndon, VA), and FBS was purchased
from Serologicals Corp. (Norcross, GA).
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Construction and production of adenoviral vectors. (i) Construc-
tion of adenoviral vectors encoding non-codon-optimized gene se-
quences: AdPAD4, AdPA63, AdPA83, AdLFn, and AdmLF7. The full-
length non-codon-optimized PA gene encoding PA83 and its signal
peptide sequence was PCR amplified with template DNA prepared from a
Sterne strain (34F2) of B. anthracis by using the specific primers 5=-GGA
TTCGGTACCACCATGAAAAAACGAAAAGTGTTAATACCA-3= and 5=-G
AATTCTCTAGACCTTATCCTATCTCATAGCCTTTTTTAGAA-3= and
cloned into a pAdApt shuttle vector to generate a pAdApt/PA83 con-
struct. pAdApt/PAD4 (encoding domain 4 of PA which includes C-ter-
minal last 139 amino acids of the PA)was provided byCharles Turnbough
(University of Alabama, Birmingham, AL). pAdApt/PA63 (encoding a
63-kDa active form of PA that includes amino acids 175 to 764 of the PA),
pAdApt/LFn (encoding amino acids 10 to 254 of LF, a truncated version of
LF that retained the N-terminal PA-binding domain without the catalytic
domain of LF [15]), and pAdApt/mLF7 (encoding the full-length but
atoxic B. anthracis LF, which has the E687C substitution [16]) were pro-
vided by Darrell Galloway (Ohio State University, Columbus, OH). The
AdPAD4, AdPA63, AdPA83, AdLFn, and AdmLF7 viral vector seeds were
created by cotransfection of the pAdApt/PAD4, pAdApt/PA63, pAdApt/
PA83, pAdAptLFn, and pAdApt/mLF7 with an Ad5 backbone plasmid
pAdeasy-1 into the PER.C6 packaging cells (17).
(ii) Construction of adenoviral vector encoding codon-optimized
gene sequences, AdtPA83hu, AdtLFnhu, and AdPA83hu. The tPA83hu
fragment, an amino-terminal human tissue plasminogen activator (tPA)
leader sequence, followed with a codon-optimized B. anthracis PA83 gene
(without the PA signal peptide sequence), and the tLFnhu fragment, the
tPA leader sequence followed by a codon-optimized fusion gene of the
LFn fragment (encoding amino acids 1 to 254) and Yersinia V fragment
were amplified by using a forward primer 5=-TAAGGGAAGCTTGCTAG
CCACCATGGATGCAATGAAGAGA-3= and a reverse primer 5=-ATGG
CTGTTAACTAGAAGGCACAGCAGATCTTCA-3=, which incorporate
theHindIII, NheI, andHpaI cleavage sites, withVR1020/humanizedPA83
and VR1020/humanizedLCRvLFn plasmids as DNA templates, respec-
tively. The PCR generated tPA83hu fragment was digested with HindIII
and HpaI and cloned into the HindIII and HpaI sites of a pAd shuttle
vector, and the PCR-generated tLFnhu fragment was digested with NheI
and HpaI and cloned into the NheI and HpaI sites of a pAd shuttle vector
to construct pAdtPA83hu and pAdtLFnhu, respectively. A codon-opti-
mized PA83 gene with its signal peptide sequence (but not the tPA leader
sequence) was synthesized and cloned into HindIII and XbaI sites of the
pAd shuttle vector to generate a pAdPA83hu. The pAdtPA83hu,
pAdtLFnhu, and pAdPA83hu plasmids were used for generation of
AdtPA83hu, AdtLFnhu, and AdPA83hu vectors as described previously
(18).
(iii) Production of adenoviral vectors. All Ad5 vectors were propa-
gated on PER.C6 cells and purified by ultracentrifugation over a cesium
chloride gradient as described previously (13). The purified Ad5 vectors
were sterilized by 0.22-m-pore-size filtration and stored at 4°C or
20°C in A195 adenoviral storage buffer (19). Ad5 vector titers were
determined by using an Adeno-X rapid titer kit (Clontech, Mountain
View, CA) on HEK293 cells. All of the insertions of above Ad5 vectors
were checked by partial DNA sequencing (The Genomics Core Facility of
the Heflin Center for Human Genetics, University of Alabama at Bir-
mingham).
Animal experiments. The B. anthracis Sterne 34F2 strain (Colorado
Serum Co., Denver, CO) is nonencapsulated (pXO2) but toxigenic
(pXO1) with PA and LF expressed from the pXO1 plasmid. Live B.
anthracis Sterne spores were mass produced and purified through gradi-
ents of Renografin-60 (Bracco Diagnostic, Princeton, NJ) as described
previously (20). A/J mouse vaccinations with adenoviral constructs, fol-
lowed by B. anthracis Sterne spore challenge, were performed at the Bat-
telle Memorial Institute (Columbus, OH; studies 613-G005625, 649-
G005625, and 675-G005625) and at the University of Alabama at
Birmingham (Birmingham, AL), respectively. Briefly, young (2- to
3-month-old) female A/J mice (Jackson Laboratory, Bar Harbor, ME)
were immunized by i.n. inoculation of 30 to 50l of Ad5 vectors into one
of the nostrils of an anesthetized mouse. Blood samples were collected
pre- and postvaccination and stored at20°C until analyzed. Bronchoal-
veolar lavage (BAL) was taken by flushing the lungs with 1.0 ml of phos-
phate-buffered saline (PBS) and stored at 20°C until analyzed. Immu-
nized A/J mice were challenged by i.n. instillation of 5  105 CFU of B.
anthracis Sterne spores (50 the 50% lethal dose [LD50]) in a volumeof
10l as previously described (20). Animals weremaintained in the animal
facility at the Battelle Memorial Institute and University of Alabama at
Birmingham. Daily care was provided by trained technicians at Battelle
Memorial Institute and University of Alabama at Birmingham Animal
Resource Center. Challenge studies were performed in designed challenge
rooms. All experiments inmicewere performed according to institutional
guidelines.
Anti-PA and anti-LF IgG and IgA antibody titers. Anti-PA and an-
ti-LF immunoglobulin G (IgG) titers in mouse serum samples were de-
termined by enzyme-linked immunosorbent assay (ELISA) using purified
PA or LF protein (List Biological Laboratories, Campbell, CA) as the cap-
ture antigen. Briefly, 96-well plates were coatedwith 100 ng of purified PA
or LF protein/well dissolved in PBS at 4°C overnight. Plates were washed
with Tris-buffered saline (TBS; 50 mM Tris-HCl, 0.15 M NaCl [pH 7.3])
and blocked with 1% bovine serum albumin in TBS. The serum samples
and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG
(Promega Corp., Madison, WI) were incubated sequentially on the plates
with extensive washing between incubations. All incubations were carried
out at 37°C for 1 h. The presence of bound antibody was detected after 10
min of incubation in the presence of -phenylenediamine substrate
(Sigma), and the absorbance was read at 490 nm using a Molecular De-
vicesmodel Precisionmicroplate reader. The endpoint was determined as
the dilution of serum producing the same optical density at 490 nm as a
1/100 dilution of preimmune serum. Sera negative at the lowest dilution
testedwere assigned endpoint titers of 1. Titers of anti-PA and anti-LF IgA
in mouse BAL samples were measured by ELISA as described above. The
second antibody used was HRP-conjugated goat anti-mouse IgA (South-
ern Biotech, Birmingham, AL).
Anti-Letx neutralizing antibody titers. Serum samples were analyzed
for anti-lethal toxin (anti-Letx) neutralizing antibodies as described for a
toxin neutralization assay (21) with modifications. RAW 264.7 mouse
macrophage cells were placed in flat-bottom 96-well microtiter plates at a
concentration of 5 104 cells/well in culture medium incubated for 24 h
at 37°C. Serum samples from each mouse were serially diluted and incu-
bated with an equal volume of Letx (200 ng of PA/ml plus 200 ng of LF/ml
in cell culture medium) for 1 h at room temperature to allow neutraliza-
tion to occur. Media from the cells in 96-well plates were aspirated and
replacedwith the serum-Letxmixture at 100l/well. Cells in control wells
were incubated with 100 l of medium only or Letx without mouse se-
rum. After20 h of incubation at 37°C, the cell viability wasmeasured by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazolium bromide (MTT)
assay as described previously (20). Samples in duplicate were read on a
Precision microplate reader (Molecular Devices) at 490 nm. The survival
of control cells without exposure to Letx was arbitrarily defined as 100%
protection, and the reading of the Letx-only wells was defined as 0%
protection. The neutralization titer was determined as the reciprocal of
the highest serum dilution resulting in 50% protection of the cells.
Anti-Ad5 neutralizing antibody assay. Anti-Ad5 neutralizing anti-
body titers were measured by incubating diluted serum samples with
wild-type (wt) Ad5 as described previously (13). Briefly, 293 cells were
placed in flat-bottom 96-well microtiter plates at a concentration of 2.5
104 cells/well in culture medium incubated for 24 h at 37°C. Serum sam-
ples from eachmouse were serially diluted in serum-free culturemedium.
Then, 60 l of each dilution was mixed with 1.7  104 infectious units
(IFU) ofwt Ad5 in 60l ofmedium containing 2%FBSwith antibiotic for
1 h at room temperature to allow neutralization to occur. Media from the
cells in 96-well plates were aspirated and replaced with 100 l of serum-
Zhang et al.
2 cvi.asm.org Clinical and Vaccine Immunology
 o
n
 February 24, 2014 by Cardiff Univ
http://cvi.asm
.org/
D
ow
nloaded from
 
Ad5mixture/well. The cells in control wells were incubated with 100l of
medium only or wt Ad5 without mouse serum. After 2 h of incubation at
37°C, the serum-Ad5mixture was replaced with cell culturemedium. Cell
viability at 4 days postinfection was determined by MTT assay. The sur-
vival of control cells without exposure to Ad5 was arbitrarily defined as
100% protection, and the readings of the Ad5-only wells were defined as
0% protection. Neutralization titer was determined as the reciprocal of
the highest serum dilution resulting in 50% protection of the cells.
Statistical analysis. All statistical analysis was performed using
GraphPad Prism version 5.04 (GraphPad Software, San Diego, CA). Log-
rank (Mantel-Cox) tests were performed for comparing survival curves
and the mean times to death (MTD) in challenged animals. One-way
analysis of variance with Tukey’s multiple-comparison post tests were
performed to compare anti-Letx neutralizing antibody titers and anti-PA
and anti-LF IgG ELISA titers. Statistical significance was set at P 0.05.
RESULTS
Codon-optimized Ad5-vectored anthrax vaccines offer better
protection against anthrax spore challenges than their cognate
counterparts. In developing the Ad5-vectored anthrax vaccines,
five Ad5 vectors—AdPAD4, AdPA63, AdPA83, AdLFn, and
AdmLF7—encoding non-codon-optimized DNA sequence for
subdomains and full length of PAor LF proteinswere constructed.
Animal experiments indicated that the Ad5 vectors encoding full-
length PA or LF were able to achieve higher levels of serum anti-
gen-specific IgG antibodies, stronger anti-Letx neutralizing anti-
body responses, and better protection against lethal anthrax spore
challenges than their truncated counterparts. However, only par-
tial protection was afforded against a 5  105 CFU B. anthracis
Sterne spore (50 the LD50) challenge after a single i.n. immu-
nization with 107 IFU of AdPA83, themost immunogenic vaccine
construct, permouse (Vaxin, Inc., unpublished data). To improve
the potency of Ad5-vectored anthrax vaccines, codon optimiza-
tion of PA and LF genes and fusion of the tPA leader sequence
approaches were applied to generate AdtPA83hu, AdtLFnhu, and
AdPA83hu. The relative immunogenicities among these Ad5 vec-
tors encoding codon-optimized and non-codon-optimized PA
and LF were then assessed by i.n. vaccination of groups A/J mice
(10 mice per group) with 107 IFU of AdPA83, AdPA83hu,
AdtPA83hu, AdmLF7, and AdtLFnhu, respectively, per mouse. A
recombinant Ad5 vector (Adtetc encoding tetanus C fragment)
served as an Ad5 vector control. Analysis of the sera by ELISA
showed that the geometric mean titers of anti-PA IgG antibody
FIG 2 Anti-PA and anti-LF IgA ELISA titers in the BAL fluid were measured
4 weeks after a single i.n. immunization with AdtPA83hu (tPAhu) or
AdtLFnhu (tLFnhu) at a dose of 107 IFU per vector. All mice immunized with
Adtetc vector controls and all preimmune sera had anti-PA and anti-LF IgA
ELISA titers of100. The results of anti-PA and anti-LF IgA ELISAs are plot-
ted as the log10 titers. Bars are geometric means of the anti-PA or anti-LF
ELISA titers.
FIG 1 Comparison of immune responses in A/J mice induced by Ad5 vectors encode codon-optimized and non-codon-optimized PA or LF genes. (A to C)
Anti-PA IgG ELISA titer (A), anti-LF IgG ELISA titer (B), and anti-Letx neutralizing antibody titer (C) inmouse serumwere compared 4 weeks after a single i.n.
immunization with AdPA83 (PA), AdPA83hu (PAhu), AdtPA83hu (tPAhu), AdmLF7 (mLF7), and AdtLFnhu (tLFnhu) at a dose of 107 IFU per vector. All mice
immunized with Adtetc control vectors and all preimmune sera had anti-PA or anti-LF IgG ELISA titers of100 and had anti-Letx neutralizing antibody titers
of8. (D) Survival of vaccinated A/J mice against a 50 LD50 B. anthracis Sterne spore challenge. The results of anti-PA and anti-LF IgG ELISAs and anti-Letx
neutralizing assays are plotted as the log10 titers. Bars are geometric mean of the anti-PA and anti-LF ELISA titers or the anti-Letx neutralizing antibody titers.
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induced by AdPA83hu and AdtPA83hu were 45.3 and 68.6 times
that induced by AdPA83 (P  0.001 for both AdPA83hu versus
AdPA83andAdtPA83huversusAdPA83;P0.05 forAdtPA83huver-
sus AdPA83hu) (Fig. 1A). The geometric mean titers of anti-LF
IgG antibody stimulated by AdtLFnhu were 4.0 times that in-
duced by AdmLF7 after 4 weeks with a single i.n. administra-
tion (Fig. 1B). To determine the functionality of antibodies to
PA and LF elicited by the immunization, the abilities of sera to
protect mouse macrophage cells from Letx mediated lysis were
measured. As shown in Fig. 1C, the highest anti-Letx antibody
titers were detected in mice immunized with AdtPA83hu. Both
AdtPA83hu and AdPA83hu could induce significantly higher
anti-Letx antibody titers than did AdPA83 (P 0.001 for both
AdPA83hu versus AdPA83 and AdtPA83hu versus AdPA83; P
 0.05 AdtPA83hu versus AdPA83hu). Furthermore, the an-
ti-LF antibodies elicited by both AdtLFnhu and AdmLF7 were
able to inhibit the cytotoxic effects of Letx (Fig. 1C). To test the
effectiveness of Ad5-vectored anthrax vaccines with regard to
protection against anthrax infection, immunized mice were
challenged with 50 LD50 B. anthracis Sterne spores after 4
weeks vaccination (Fig. 1D). All mice receiving the control
Adtetc died within 6 days, and 100% of the mice vaccinated
with AdPA83hu and AdtPA83hu survived the spore challenge.
Protection was also achieved in 70, 30, and 40% of the mice
vaccinated with AdPA83, AdmLF7, and AdtLFnhu, respec-
tively (P  0.05 for both AdPA83hu versus AdPA83 and
AdtPA83hu versus AdPA83; P 0.001 for both AdPA83 versus
Adtetc and AdtLFnhu versus Adtetc; P  0.05 AdmLF7 versus
Adtetc). These results indicate that optimization of codon us-
age improved the protection potency of an AdVAV and fusion
with the tPA leader sequence may further enhance its immu-
nogenicity.
Intranasal vaccination with Ad5-vectored anthrax vaccines
induces secretory IgA antibodies. Intranasal vaccination is an
effective approach for optimal protection of mucosal surfaces by
inducingmucosal and systemic immunity. To test the feasibility of
AdVAVs for induction of mucosal immunity, groups of A/J mice
(10mice per group)were immunizedwith 107 IFUofAdtPA83hu,
AdtLFnhu, or Adtetc/mouse. Mouse BAL samples from immu-
nizedmice were collected at 4 weeks postvaccination and assessed
FIG 3 Kinetics of immune responses in A/Jmice. (A to C) The anti-PA IgG ELISA titer (A), anti-LF IgG ELISA titer (B), and anti-Letx neutralizing antibody titer
(C) in mouse serum were measured at the indicated time points after a single i.n. immunization with 107 IFU of AdtPA83hu (tPAhu), 107 IFU of AdtLFnhu
(tLFnhu), or 107 IFU of AdtPA83hu plus 107 IFU of AdtLF4hu (tPAhutLFnhu). All mice immunized with 107 IFU of Adtetc vectors and all preimmune sera
had anti-PA and anti-LF IgG ELISA titers of 100 and had anti-Letx neutralizing antibody titers of 8. The results of anti-PA and anti-LF IgG ELISAs and
anti-Letx neutralizing assays are plotted as the log10 titers. All of the data are shown as geometric means with 95% confidence intervals of 8 to 10mice per group.
(D and E) Protection of A/J mice against a 50 LD50 B. anthracis Sterne spore challenge at 2 weeks (E) and 56 weeks (D) postimmunization.
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by ELISA. As shown in Fig. 2, strong anti-PA and anti-LF secretory
IgA antibodies were induced by AdtPA83hu and AdtLFnhu, re-
spectively (Fig. 2).
Intranasal immunization of Ad-vectored anthrax vaccines
elicits partial protective immunity within 2 weeks, and the ro-
bust immunity lasts at least 1 year.To determine the kinetics and
durability of the immune response, groups of A/J mice (10 mice
per group) with a single i.n. administration of 107 IFU of
AdtPA83hu, AdtLFnhu, or both/mouse were evaluated. Signifi-
cant levels of anti-PA IgG antibody (Fig. 3A), anti-LF IgG anti-
body (Fig. 3B), and anti-Letx antibody (Fig. 3C) were detected
after 2 weeks immunization, and the antibody titers increased and
peaked around week 4 and remained unchanged to the time of
spore challenge at week 56 (P  0.05 for the anti-Letx antibody
titers at 4 weeks postvaccination versus the anti-Letx antibody
titers at 56 weeks postvaccination in animals immunized with
AdtPA83hu, AdtLFnhu, or both). All animals vaccinated with
AdtPA83hu and AdtPA83huAdtLFnhu and three of nine mice
immunized only with AdtLFnhu survived the challenge (Fig. 3D).
To determine the onset of protective immunity, groups of A/J
mice were challenged 2 weeks after vaccination (Fig. 3E). Thirty
percent in the AdtPA83hu-immunized group and 50% in the
AdtPA83huAdtLFnhu-vaccinated group survived (P  0.001
for both AdtPA83hu versus Adtetc and AdtPA83huAdtLFnhu
versus Adtetc). All mice receiving Adtetc or AdtLFnhu alone died
after spore challenge. However, the mean time to death (MTD)
was 4.8 days for mice immunized with AdtLFnhu, while theMTD
for Adtetc-immunized control mice was 3.3 days (P 0.05). Our
findings demonstrate that a single i.n. vaccinationwith anAdVAV
can provide rapid and long-term protection against a lethal chal-
lenge of B. anthracis spores. The anti-LF immune responses in-
duced by AdtLFnhu increase the anti-Letx antibody titers mini-
mally and enhanced the protective immunity induced by
AdtPA83hu (Fig. 3C and E), although the differences between
AdtLFnhuAdtPA83hu and AdtPA83hu alone were not statisti-
cally significant.
Preexisting immunity to Ad5 did not impair the potency of
an Ad-vectored nasal anthrax vaccine.To determine the effect of
preexisting anti-Ad5 immunity on i.n. vaccination of an AdVAV,
A/J mice (12 animals per group) were primed by i.n. installation
with 107 IFU of wt Ad5/mouse or control buffer on day 0. On day
14, serum anti-Ad5 neutralizing antibody titers ranging from 1:32
to 1:256 (with a geometric mean at 1:57) were detected in mice
primed with wt Ad5 on day 0. These mice were i.n. immunized
with 108 IFU of AdtPA83hu/mouse plus 5.4 106 IFU of AdmIn-
hAhu/mouse (an Ad5 vector encoding B. anthracis immune in-
hibitor A gene) (high dose), 107 IFU of AdtPA83hu/mouse plus
5.4  105 IFU of AdmInhAhu/mouse (median dose), 106 IFU of
AdtPA83hu/mouse plus 5.4  104 IFU of AdmInhAhu/mouse
(low dose) on day 14. One group of mice without wt Ad5 priming
were immunized with 108 IFU of AdtPA83hu plus 5.4 106 IFU
of AdmInhAhu (high dose) as controls. Although vaccination of
mice without wt Ad5 priming produced slightly higher anti-PA
IgG and anti-Letx antibody titers, the differences between two
groups (high dose) were not statistically significant (P 0.05 for
both anti-PA IgG and anti-Letx antibody titers) (Fig. 4). All of the
mice immunizedwithAdthuPA83plusAdmInhAhuwith orwith-
out wt Ad5 priming were protected against a 50 LD50 B. anthra-
cis Sterne spore challenge. All animals in control groups suc-
cumbed to the anthrax spore challenge (Table 1). These results
demonstrated that animals possessing high levels of antibodies
against Ad5 can be effectively vaccinated against anthrax with an
i.n. AdVAV.
DISCUSSION
To develop the next generation of safe and effective anthrax vac-
cines, it is crucial that the vaccine can induce rapid and sustained
protective immunity in a single-dose regimenwith no adverse side
effects. Manufacturing, distribution, and administration must be
rapid, easy, and economical. To address these requirements, sev-
eral AdVAVs expressing PA or LF proteins were tested. Certain
attributes of Ad5 vectors make them attractive for use as nasal
vaccine platforms. (i) Replication-competent adenovirus (RCA)-
free Ad5-vectored vaccines can be manufactured in PER.C6 cells
quickly using disposable manufacturing technologies (17, 18, 22).
(ii) Novel formulations allow Ad5-vectored vaccines to be stored
in liquid buffer (19) or as lyophilized dry powder (23) at 4°C for at
least a year and newly developed thermostabilization techniques
allowAd5 vectors to be stored at room temperature up to 45°C for
6 months with minimal declining infectivity (24). (iii) Ad5-vec-
tored vaccines may be self-administered with a spray in an emer-
gency event.
FIG 4 Immunogenicity of Ad-vectored nasal anthrax vaccines in the presence of preexisting anti-Ad5 vector immunity. The A/J mice were first i.n. inoculated
with 107 IFU of wt Ad5 per mouse and then after 2 weeks were i.n. immunized with 108 IFU of AdtPA83hu plus 5.4 106 IFU of AdmInhAhu (High), 107 IFU
of AdtPA83hu plus 5.4 105 IFU of AdmInhAhu (Median), or 106 IFU of AdtPA83hu plus 5.4 104 IFU of AdmInhAhu (Low). One group ofmice without
Ad5 priming were immunized with108 IFU of AdtPA83hu plus 5.4 106 IFU of AdmInhAhu (High) as controls. Anti-PA IgG ELISA titers (A) and anti-Letx
neutralizing antibody titers (B) were determined at 4 weeks postimmunization. The results of the anti-PA IgG ELISAs and anti-Letx neutralizing assays are
plotted as log10 titers. Bars indicate geometric means of the anti-PA ELISA titers or anti-Letx neutralizing antibody titers.
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In research for new anthrax vaccines, numerous DNA con-
structs and viral vectors encoding codon-optimized or non-
codon-optimized anthrax immunogens have been tested in an-
thrax vaccine studies, but the protective efficacies as vaccine
candidates have not been compared in a same system. In the pres-
ent study, we compared the relative levels of serum antigen-spe-
cific antibody titers and anti-Letx neutralizing antibody titers, as
well as the strength of protective immunity induced by Ad5 vec-
tors encoding codon-optimized or non-codon-optimized PA and
LF genes in the A/J mouse model. Our results suggest that codon
optimization of anthrax immunogens can enhance the humoral
immune response of an AdVAV (Fig. 1), although the levels of
protection against a lethal spore challenge among the AdPA83,
AdPA83hu, and AdtPA83hu groups were not statistically signifi-
cant in this particular experiment (Fig. 1D).
We demonstrated here that 100% of A/J mice can be protected
from a lethal anthrax spore challenge after a single-dose i.n. vac-
cination with AdtPA83hu vectors (Fig. 1D and 3D). The duration
of immunity with AdtPA83hu and/or AdtLFnhu has been mea-
sured in mice with demonstrable high serum anti-Letx antibody
titers and antigen specific IgG titers that persist for at least 1 year
(Fig. 3A to C). Moreover, partial protective immune responses
can be rapidly generatedwithin 2weeks (Fig. 3E). These results are
consistent with previous reports that Ad5-vectored vaccines could
provide rapid and sustained protective immunity (11, 12, 25–28).
There is compelling evidence that the upper respiratory tract
and other mucosal tissues are early targets of inhalational anthrax
spore infection (29–31). A nasal anthrax vaccine that potentially
induces both systemic and respiratory mucosal immune re-
sponses may be a favorable candidate against inhalational anthrax
(32–34). Nasal delivery of an Ad5-vectored human immunodefi-
ciency virus vaccine induced stronger mucosal immunity (35),
and a nasal Ad5-vectored vaccine provided better protection
against airway Mycobacterium tuberculosis than intramuscularly
injected Ad5-vectored vaccines (36). In contrast to vaccines re-
quiring artificial adjuvants and multiple immunizations for in-
ducing sufficient mucosal immunity, an AdVAV can provide self-
adjuvanting activity (37) capable of eliciting high titers of secreted
IgA in animals after single-dose administration (Fig. 2). In addi-
tion, i.n. Ad5-vectored vaccines can also induce strong cell-medi-
ated immunity (38, 39). It would be interesting to test whether an
AdVAV can elicit cellular immune responses that may be benefi-
cial in combating early infection when spores are engulfed by pul-
monary phagocytes.
Studies by us and others indicate that administration of Ad5-
vectored vaccines via the i.n. route might overcome preexisting
immunity against theAd5 vector (14, 40–42). In the present study,
we demonstrated that an AdVAV, administered i.n. 2 weeks after
priming with wt Ad5, could effectively immunize A/J mice (Fig.
4). Additional nonclinical and clinical information is needed to
clarify the influence of the preexisting Ad5 immunity and to con-
firm the suitability of an i.n. AdVAV for human use.
Anthrax vaccines that can induce immune responses against
both PA and an additional component such as PGA (43), LF (21),
or Bacillus collagen-like protein of anthracis (BclA) (44) may be
more effective against anthrax than the vaccines based on PA
alone. Consistent with previous reports (21, 45), we observed that
immune responses to LF alone could provide partial protection
against a lethal anthrax spore challenge (Fig. 1D and 3D). Our
study also suggested thatmultivalent AdVAVs could bemixed and
delivered simultaneously (Fig. 3C and E). Additional testing to
determine whether Ad5-vectored anthrax vaccines encoding PA
and additional components would provide better protection
against anthrax by targeting the early stages of spore infection as
well as the toxins produced by the vegetative bacilli is warranted.
In summary, the data presented here show that (i) i.n. AdVAV
can induce both systemic and mucosa immunity responses, (ii)
i.n. immunization with AdtPA83hu provides full protection in
vaccinated A/Jmice against a lethal anthrax spore challenge, (iii) a
single dose of AdVAV can elicit rapid and sustained protective
immunity, (iv) AdVAV can effectively immunize A/J mice in the
presence of preexisting immunity to Ad5, and (v) AdVAV has
merit for further studies in the search a new and improved vaccine
against aerosolized anthrax spores.
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